Clinical Trial Update: Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic Melanoma [Phase 2]

View source ↗

Summary

A Phase II study evaluating L19-IL2 in combination with dacarbazine for metastatic melanoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Dacarbazine (dacarbazine)
• L19-IL2 (Interleukin-2 fused to the L19 antibody (L19-IL2))

Snippet

Sponsor: Philogen S.p.A. | Conditions: Metastatic Melanoma | Phase 2 | Status: TERMINATED